Chemotherapy-Induced Anemia Market Report 2025

The chemotherapy-induced anemia market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increased prevalence of cancer and chemotherapy treatments, aging population leading to higher cancer incidence, expansion of chemotherapy drugs and regimens, improvement in overall cancer survival rates, awareness and diagnosis of anemia as a side effect.

The chemotherapy-induced anemia market size is expected to see strong growth in the next few years. It will grow to $3.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of supportive care in oncology, rise in healthcare expenditure and infrastructure, personalized medicine and targeted cancer therapies, integration of biomarker-driven treatment approaches, increasing focus on early detection and intervention, integration of digital health technologies in patient management. Major trends in the forecast period include innovation of novel chemotherapy agents, integration of ml, advancements in cancer research and treatment protocols, integration of ai, collaboration between pharmaceutical companies and healthcare providers.

The anticipated growth in the chemotherapy-induced anemia market is expected to be propelled by the high prevalence of cancer and anemia. Cancer, characterized by uncontrolled cell growth and spreading to other parts of the body, often leads to chemotherapy-induced anemia (CIA) in patients undergoing aggressive chemotherapy, with or without radiation therapy. Medications designed to stimulate red blood cell production in the bone marrow are commonly used to address chemotherapy-induced anemia. For instance, Cancer Research UK projects a 3% increase in the incidence of head and neck cancer in the UK from 2023 to 2025, with a corresponding 12% rise in deaths due to head and neck cancers during the same period. Consequently, the elevated prevalence of cancer and anemia contributes to the growth of the chemotherapy-induced anemia market.

The increase in research and development expenditure is expected to drive the growth of the chemotherapy-induced anemia market in the future. Research and development investment refers to the expenses incurred by a company to develop, design, and enhance its products. Higher R&D spending can foster innovation and productivity in creating and formulating new drugs to treat chemotherapy-induced anemia. For instance, in April 2024, the Office for National Statistics, a UK government department, reported that the UK government's net expenditure on research and development (excluding EU contributions) rose to £15.5 billion ($19.375 billion) in 2022, marking a 10.5% increase from £14 billion ($17.5 billion) in 2021. Furthermore, total net expenditure on R&D, including EU contributions and knowledge transfer activities, reached £16.4 billion ($20.5 billion) in 2022, reflecting an 8.9% rise from £15 billion ($18.75 billion) in 2021. Therefore, the rising R&D expenditure is driving the chemotherapy-induced anemia market forward.

Major companies in the chemotherapy-induced anemia market are focusing on developing innovative products, such as biosimilars, to enhance treatment efficacy and reduce costs. Biosimilars are biologic medical products that closely resemble an already approved reference biologic drug, showing no significant differences in safety, purity, or effectiveness. They provide more affordable alternatives to expensive biologic treatments while maintaining similar therapeutic outcomes. For example, in November 2022, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, launched RELEUKO (filgrastim-ayow), which references Neupogen®. This product is primarily indicated for treating neutropenia, a common condition among chemotherapy patients. RELEUKO offers significant benefits for cancer treatment by reducing the incidence of infections related to febrile neutropenia in patients receiving myelosuppressive chemotherapy, thereby enhancing safety and recovery. Additionally, RELEUKO aids in shortening the time to neutrophil recovery and reduces the duration of fever following chemotherapy for acute myeloid leukemia, helping to mitigate the complications of neutropenia in patients undergoing bone marrow transplantation.

Major companies in the chemotherapy-induced anemia market are focusing on developing technological advancements, such as Ojjaara (momelotinib), to enhance treatment options and improve patient outcomes for those affected by anemia related to cancer therapies. The name "Ojjaara" is inspired by the word "Ojaara," reflecting a connection to healing and wellness. For instance, in September 2023, Ojjaara (momelotinib) was developed by GSK (GlaxoSmithKline), a UK-based company. This drug represents a significant advancement in the treatment of myelofibrosis, particularly for patients with anemia. Ojjaara works by inhibiting key pathways to improve blood counts, enhance quality of life, and reduce the need for blood transfusions, making it the first and only therapy specifically indicated for this condition.

In August 2022, CSL Limited, an Australia-based biotechnology company, acquired Vifor Pharma AG for an undisclosed amount. This strategic acquisition aimed to diversify CSL's business by integrating Vifor's franchises, thereby strengthening CSL's position in a high-growth and less competitive sector. Vifor Pharma AG is a Switzerland-based pharmaceutical company with a pipeline of drugs for chemotherapy-induced anemia.

Major companies operating in the chemotherapy-induced anemia market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., Aileron Therapeutics Inc.

North America was the largest region in the chemotherapy-induced anemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy-induced anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Chemotherapy-Induced Anemia is a decrease in red blood cells resulting from chemotherapy treatments, which can lead to symptoms such as fatigue and weakness. Managing this condition is essential for improving patients' quality of life during cancer treatment. Treatment often involves erythropoiesis-stimulating agents or blood transfusions to help alleviate the symptoms and restore red blood cell levels.

The various categories of chemotherapy-induced anemia include mild, moderate, severe, and life-threatening anemia. Mild anemia denotes a condition where an individual has hemoglobin levels below the standard range. Treatment protocols, including red blood cell (RBC) transfusion, erythropoiesis-stimulating agents (ESAs), and iron supplementation, are applicable in diverse end-user settings such as hospitals, ambulatory surgical centers, multispecialty clinics, cancer research centers, and cancer rehabilitation centers.

The chemotherapy-induced anemia report is one of a series of new reports that provides chemotherapy-induced anemia market statistics, including the chemotherapy-induced anemia industry's global market size, regional shares, competitors with chemotherapy-induced anemia market share, detailed chemotherapy-induced anemia market segments, market trends, and opportunities, and any further data you may need to thrive in the chemotherapy-induced anemia industry. This chemotherapy-induced anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chemotherapy-induced anemia market consists of sales of androxy oral, epoetin alfa injection, epogen injection, procrit injection, and aranesp injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.